stockrowWest Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +56.7%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow WST
Alert me
West Pharmaceutical Services, Inc. 8-K filed Oct 26, 2026
1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
What it says
West Pharmaceutical Services entered a new five-year unsecured credit agreement on October 26, 2026, providing a $750 million revolving facility and a $200 million term loan. It used new borrowings to repay and terminate its 2019 credit agreement, under which $130.0 million was outstanding, with no early termination penalties.
-
The new agreement includes revolving, term loan, letter-of-credit and swing-line capacity, with term-loan amortization beginning March 31, 2028.
provides for revolving advances up to an aggregate principal amount of $750 million at any one time outstanding
-
The term loan was advanced on the effective date; quarterly payments range from $1.25 million to $2.5 million, with the remaining balance due at maturity.
provides for a term loan advance on the Effective Date in an aggregate principal amount of $200 million
-
The company repaid its prior credit agreement in full and terminated it on October 26, 2026.
$130.0 million in aggregate principal amount was outstanding under the Existing Credit Agreement, which was repaid in full on the Effective Date.
-
The new agreement limits the Net Leverage Ratio to 3.50 to 1.0, or 4.00 to 1.0 during specified material acquisition periods.
to not more than 3.50 to 1.0 (or 4.00 to 1.0 during material acquisition periods, subject to certain limitations).